USING AI AND NEUROIMAGING

ADVANCED CLINICAL TRIALS AND THERAPIES

OPTIMIZED THERAPIES

OPTIMAL MEASURES

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

OUR CLIENTS

OUR CLIENTS

PHARMAS

A solution for supporting the data-driven selection of patients, monitoring drug performance and assessing the clinical trials outcomes.

HEALTHCARE PROVIDERS

A solution that offers early and extensive insights to assist in personalizing therapies for improved patient care.

NEWS

Qynapse exhibits at the 2019 Alzheimer’s Association International Conference® (AAIC®) in Los Angeles, CA

From July 14 – 18th, Qynapse will be part of the 2019 Alzheimer’s Association International Conference® (AAIC®) held in Los Angeles, California

Qynapse releases new validation results of QyScore® performance

QyScore®, the software by Qynapse that provides automated volumetric measurements of brain structures, takes a big step forward with the validation of performance for one of its major functionalities

Qynapse attended the 14th AD/PD International Conference

Qynapse took part in the 2019 International Conference on Alzheimer’s & Parkinson’s Disease (AD/PDTM) in Lisbon, Portugal from March 26 – 31st

Qynapse partners with AG Mednet

Qynapse is pleased to announce the signing of a partnership agreement with AG Mednet, the leading provider of medical trials data management services, for the use of its Judi imaging adjudication system